CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: Based on our evidence for CML immune subversion of iNKT-cell activities (22, 27), we first investigated possible dysfunctions of this new innate CD8 T subset (for gating strategy, see Figure 1A) in CML patients at diagnosis (CML-CP).